<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR312.html">Part 312
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 312.40  General requirements for use of an investigational new
                            </h3>
                            <p class="depth1"><em>(a)</em> An investigational new drug may be used in a clinical investigation if the following conditions are met:</p><p class="depth2"><em>(1)</em> The sponsor of the investigation submits an IND for the drug to FDA; the IND is in effect under paragraph (b) of this section; and the sponsor complies with all applicable requirements in this part and parts 50 and 56 with respect to the conduct of the clinical investigations; and</p><p class="depth2"><em>(2)</em> Each participating investigator conducts his or her investigation in compliance with the requirements of this part and parts 50 and 56.</p><p class="depth1"><em>(b)</em> An IND goes into effect:</p><p class="depth2"><em>(1)</em> Thirty days after FDA receives the IND, unless FDA notifies the sponsor that the investigations described in

the IND are subject to a clinical hold under Sec. 312.42; or</p><p class="depth2"><em>(2)</em> On earlier notification by FDA that the clinical investigations in the IND may begin. FDA will notify the sponsor in writing of the date it receives the IND.</p><p class="depth1"><em>(c)</em> A sponsor may ship an investigational new drug to investigators named in the IND:</p><p class="depth2"><em>(1)</em> Thirty days after FDA receives the IND; or</p><p class="depth2"><em>(2)</em> On earlier FDA authorization to ship the drug.</p><p class="depth1"><em>(d)</em> An investigator may not administer an investigational new drug to human subjects until the IND goes into effect under paragraph (b) of this section.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
